DrugPatentWatch Database Preview
Drugs in Development Information for Relacorilant
» See Plans and Pricing
What is the development status for investigational drug Relacorilant?
Relacorilant is an investigational drug.
There have been 11 clinical trials for Relacorilant.
The most recent clinical trial was a Phase 1 trial, which was initiated on October 1st 2018.
The most common disease conditions in clinical trials are Cushing Syndrome, Syndrome, and Carcinoma. The leading clinical trial sponsors are Corcept Therapeutics, University of Chicago, and National Cancer Institute (NCI).
There are eleven US patents protecting this investigational drug and eighty-one international patents.
Summary for Relacorilant
| US Patents | 11 |
| International Patents | 81 |
| US Patent Applications | 13 |
| WIPO Patent Applications | 11 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 1 (2018-10-01) |
| Vendors | 7 |
Recent Clinical Trials for Relacorilant
| Title | Sponsor | Phase |
|---|---|---|
| Study of Relacorilant in Combination With Pembrolizumab for Patients With Adrenocortical Carcinoma With Excess Glucocorticoid Production | Corcept Therapeutics | Phase 1 |
| Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma | Corcept Therapeutics | Phase 3 |
| Efficacy and Safety of Relacorilant in Patients With Cortisol-Secreting Adrenal Adenomas | Corcept Therapeutics | Phase 3 |
Clinical Trial Summary for Relacorilant
Top disease conditions for Relacorilant
Top clinical trial sponsors for Relacorilant
US Patents for Relacorilant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Relacorilant | Start Trial | Glucocorticoid receptor modulators to treat pancreatic cancer | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Treatment and differential diagnosis of Cushing's disease and ectopic Cushing's syndrome | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Glucocorticoid receptor modulators to treat cervical cancer | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Glucocorticoid receptor modulators to treat pancreatic cancer | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| Relacorilant | Start Trial | Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators | Corcept Therapeutics, Inc. (Menlo Park, CA) | Start Trial |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Relacorilant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Relacorilant | Australia | AU2017323636 | 2036-09-09 | Start Trial |
| Relacorilant | Brazil | BR112019004322 | 2036-09-09 | Start Trial |
| Relacorilant | Canada | CA3034114 | 2036-09-09 | Start Trial |
| Relacorilant | China | CN109689044 | 2036-09-09 | Start Trial |
| Relacorilant | European Patent Office | EP3509584 | 2036-09-09 | Start Trial |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
